An Overlooked Truth About The Healthiest Way To Age
Experts in finance tell us that the best retirement plan is reaching your financial goals. That may give you peace of mind about your lifestyle in the future. Of course it's important, but what about the fundamental need to age well as you enjoy your retirement years? Financial advisors are vague on that, as it's not their area of expertise.
La Crema triathlon, June 2025
Health experts, on the other hand, remind us that all the money in the world doesn't do much good if you lose your health. We tend to focus more on financial safety than we do on a lifestyle that will allow us to live better in our later years. We think of relaxing, traveling, enjoying free time after years of putting in hard work at the jobs we had. Do we ever contemplate that those retirement years need to include something hard? By this I mean something physically challenging.
Researchers have known for years that exercise helps preserve brain function, especially later in life o. And yet, According to the CDC, only about 24% of adults in the United States meet the recommended guidelines for both aerobic and muscle-strengthening activities. The minimum recommendation is about 150 minutes of moderate-intensity aerobic activity per week and muscle-strengthening activities at least two days a week. Brisk walking is readily available but most people don't even do that. Before retirement, the most common excuse is 'I don't have time'. But in retirement, you do. What now?
What Do We See Among Those In Declining Health After Retirement?
As a consultant in the aging field, I see plenty of impaired older adults. Some are in their 60s and 70s. Many more are in their 80s and beyond, still living on, but with multiple chronic illnesses. Their families are struggling with how to best care for them as their health declines. The wealthiest ones are not spared from these chronic diseases. The difference between them and their less financially secure age-mates is that those who have ample resources can afford the best care.
What Does It Cost?
In one real life example, a retired professional who has a life threatening illness is going downhill fast. He is in a high end private nursing home with their staff on hand and a full time, private 'companion care' person at this side 24/7 so he won't try to get out of bed and fall. It costs him $50,000 a month to be there. I don't think he planned on spending the last part of his life that way. Was his condition preventable?
Preventing Or At Least Delaying Chronic Illness Is Possible
Exercise class, boxing, weights—anything can be a challenge
As a witness to so much decline, dementia, extensive medical need and family stress over the aging parents we see in our consulting work at AgingParents.com, I am fearful. I don't want to be like that! I'm willing to take in the advice of gurus like Andrew Huberman, neurobiologist at Stanford University, who has a popular podcast. He was not the first one to suggest that hard exercise can help us live better longer. He has highlighted the concept. Scientists like him promote the idea of preventing chronic illness. It's work. I accept that. I've adopted the strategy of prevention for a few years now and I make it a mission. He urges us to do hard things. OK. Got it. I found my hard things.
Pick Your Own Physical 'Hard Thing'
What seems hard will be different for each person. Some who have never exercised before struggle to walk around the block. And that walk around the block can gradually get faster. Then it can extend to two blocks, and so on. For someone who has never joined a group to exercise, it might be learning to play pickleball. For those who seriously want to slow the muscle loss that accompanies aging, they will get some light weights and use them at home, or go to a gym and keep it up. The point is, you need to see it as a physical challenge. As one does this, the challenge changes and you can keep adapting to what 'hard' means to you personally.
My Journey With AgingTriathlon June, 2022, Carolyn Rosenblatt
At 63, I had retired from a very stressful second career and I wanted to exercise more. My nursing background (first career) had shown me that a healthy lifestyle absolutely had to include aerobic exercise very regularly. The lessons from thousands of patients I had been responsible for attending to taught me a lot about who stayed healthy, and who got sick. Who recovered faster was a lesson too. So, crazy at is seemed, I took up the multi-sport challenge of triathlon: swim, bike and run together, back to back, in each event. I picked only the short distance ones, never any long hours, all day things. That was my hard thing. It still is at age 77. I'm not a particularly talented athlete in any of the three parts. But I do get to the finish line and am overjoyed to cross it at this point in life.
Now, of course multi-sport is not for most older people. Too many can't run anymore if they ever did. And other limitations get in the way of something that vigorous. Nor is anything that tough necessary to prevent chronic illness. But doing something hard, often, is likely necessary if you want to keep your independence and stave off what so many older people face in their retirement years. So far, it's working for this elder. No chronic illness, no prescription medications, normal blood work and all that in my physical exams. Thank you, triathlon.
The Takeaway
As you look at retirement ahead, or maybe now, pick something physically challenging for yourself to start. Get off the couch and do something you personally see as your own 'hard thing'. It doesn't have to be 'killer', just challenging. There is no need to compare yourself to anyone else. There is a need to commit to your own healthy aging. If you don't want to lose your own precious independence, it will take work. It is not magic or just luck. No doctor and no pill can do it for you. It is a choice you can make to live better longer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
40 minutes ago
- Forbes
A Compound Made From Shrimp Shells Can Rid The Body Of Microplastics
For those unaware of the extent of the problem, microplastics (MPs) are said to be in essentially every person in every part of the world. Ice samples from the poles and tissue samples from the penis show the extent of penetration. Given that these pieces of plastic have been found in placenta samples and reproductive organs, we can say that children are being subjected to plastic exposure from birth. To what degree these nano and microplastics will hurt humans is still debated and research is ongoing, and the FDA states that they'll take regulatory action when adverse effects are known. However, the reason that people prefer to avoid becoming plasticized is the conventional wisdom that having small pieces of plastic within our immune cells, nerve cells, and altering which genes are expressed is something we'd want to avoid. There's certainly no known benefit. Microplastics have ben detected basically everywhere, including the brain and penis. Recent studies discuss the 'ubiquitous' extent of microplastics and their varied effects. Kidney death, liver inflammation, oxidative stress, cellular toxicity, alterations in gene expression and changes to the DNA itself are some of the observed effects of microplastic exposure. I will hypothesize that there's potentially a link between nanoplastics and mental wellbeing. Not just from the obvious observation that plastics in the brain are bad, although this is true; I instead refer to the interference that our gastrointestinal microbiota are suffering with their extracellular vesicles because of microplastics. Understanding the brain-gut-microbe axis and the effect that our intestinal flora there have an impact on our neurological function, one may observe that altering this intestinal environment with nanoplastics can have an effect on mental wellbeing. If you do start depressed, try milk aromatherapy. It shows promise in rats depressed because of gut-brain issues. The Dentist For those of us who don't enjoy visits to the dentist, we have reasons to be validated. Different materials are used in different dental practices, but a lot of them are plastic or packaged in plastic. By the nature of installing implants that will be subjected to the wear and tear of using one's mouth in daily life, microplastics are created and ingested. Other procedures like polishing restorations, ceramic crowns, using elastics, orthodontic appliances, and so on can generate particles. Think about the plastic fibers on the plastic toothbrush you grind against your teeth twice a day. Should we go back to chewing spruce sap? Remedies Chitin is a compound found in mushrooms and the exoskeletons of crustaceans and insects. Chitosan is easily made from chitin. It's used as a dietary supplement and sold to help consumers feel full, block fat absorption and lower cholesterol. Good for wound care as well. We ought to produce more of it and make it mainstream because we have another important reason to like it. A new study has shown that it can benefit our well-being in a novel and needed way: ridding our bodies of microplastics. The study was short but revealing, and I hope it will be reproduced with longer durations and human subjects. The researchers share two important conclusions. For even short periods of ingestion, microplastics accrue in the digestive tract, primarily the cecum which is the pouch between the small intestine and colon. Assuming that chemicals can leach from these plastics and that the particles themselves will eventually absorb into the wider body, it's clearly advantageous to expel this poison before it accrues/accumulates. The group of rats that was fed a diet supplemented with chitosan expelled more MPs that any of the other groups. Intriguingly and encouragingly for me, over a few days the rats released more MPs than they took in. This suggests that chitosan won't just block absorption of current MPs, but in fact facilitate the cleansing of the colon of recently ingested microplastics. Further, after the rats were euthanized and dissected, the chitosan group had the lightest colons which suggests that they had the least total waste accumulated. As side effects for adding chitosan to one's diet are minimal beyond some stomach upset, UNLESS YOU ARE ALLERGIC TO SHELLFISH OR MUSHROOMS, it seems like a reasonable addition. This is not medical advice and as I said, I look forward to studies done with humans for longer periods to provide us with more information. With said I'm intrigued. Singapore. Green buildings trap microplastics, clean the air and water, and cool the city. Prevention A better way to go than solving a problem is to prevent it. Microplastics come from plastics, and despite some laws and public initiatives, the industry is vital and won't fade away naturally. Proactive investment in alternatives will bring about a whole society shift; personal choice is not an option here. Plastic is ubiquitous and a consumer doesn't have a real option to move away from it. Our tap water and the air we breathe are contaminated, so we must do more than avoid microwaving food in plastic containers, or stop buying items packaged in plastic. If anyone has been to any store ever, they would know that this is impossible. Everything is wrapped in plastic. To exist in the modern world is to be a creator of waste; even the well-intentioned can do little more than be frustrated. Green roofs are 97.5% effective in removing microplastics. They're generally good for retaining storm water, cleaning the air and runoff, which lessens the work of wastewater treatment plants. Green roofs can contribute to an urban cooling effect, countering the Urban Head Island (UHI) problem. Singapore has been a prime example of this for years. Now, we find another reason to widely adopt the practice in every city, immediately. Singapore exemplifies greening a city to everyone's benefit. Great Pacific Garbage Patch Removing what's already been released is a net benefit. When considering the scale of the undertaking to clean the North Pacific Garbage Patch and the greenhouse gasses that will be released or the marine life that will be interfered with, it isn't immediately clear what the best approach might be. Leaving it and hoping a reef grows on top of it could make sense, given the rubber tire reef projects we've all heard about. A comparative analysis of the Ocean Cleanup shows that while there will be some impact from action, the effect of doing nothing is significantly worse. Proactive action where possible to remove what's been released before it continues to break down into microplastics and nano plastics is a viable strategy for long term environmental health. In the scenario presented, plastic pollution levels drop to below what's considered a safe limit. Inaction has the higher cost. Leaving plastics in the oceans will be more damaging than removal. Complex problems can't be solved with simple solutions. Plastics can't be completely replaced, but we can adapt the ways we use them and consider novel strategies to mitigate their harm. When these strategies prove themselves to be effective, they ought to be systematically applied.
New York Times
an hour ago
- New York Times
A Hospital Was in Critical Condition. Could $1.1 Billion Fix It?
During the past quarter century, more than a dozen New York City hospitals have closed. The causes of death have been many: changing economics, deregulation, less government support, a shift toward more outpatient treatment. It seemed likely that University Hospital at Downstate in East Flatbush, Brooklyn, would soon join that casualty list, especially when state officials began formulating a plan last year for the hospital's demise. After all, the medical center, part of SUNY Downstate Health Sciences University, had hemorrhaged money and patients for years. A far larger hospital sits directly across the street, ensuring that the neighborhood — plagued with high rates of diabetes, hypertension and kidney disease — would not be without medical care. But then something unexpected happened. The state decided to commit $1.1 billion to University Hospital for renovations and a new outpatient facility, a stunning reversal propelled by fervent local opposition to the closing of the 342-bed hospital. When the hospital's future was in doubt, state legislators and community activists demanded that the state find the money to keep it open. Pastors spoke about it in their Sunday sermons. Rallies to save the hospital drew speakers including the Rev. Al Sharpton and Randi Weingarten, the president of the American Federation of Teachers, a major union. And patients mobilized to save their hospital, even though the federal government gives it only one star out of five in its quality rating. By the end, the administration of Gov. Kathy Hochul enthusiastically came around to the idea of shoring up the hospital instead of shutting it down. 'Let's say that again, it sounds so good: $1 billion,' Ms. Hochul, a Democrat, said at a news conference this month at SUNY Downstate, announcing the sum that the state was providing for improvements. The money is expected to go toward renovating the hospital and expanding cancer and cardiac care. Want all of The Times? Subscribe.
Medscape
an hour ago
- Medscape
AAD Updates AD Guidelines With Four New Treatment Picks
The American Academy of Dermatology (AAD) recently issued a focused update to its guidelines on the management of atopic dermatitis (AD) in adults, strongly recommending four recently approved therapies: tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab (in combination with topical therapy). These additions reflect high-certainty evidence supporting both efficacy and safety, according to the workgroup's systematic review published in the Journal of the American Academy of Dermatology . Robert Sidbury, MD Asked to comment on the updates, one of the authors, Robert Sidbury, MD, cochair of the guideline committee and chief of dermatology at Seattle Children's Hospital, Seattle, called the rapid need for a guideline update 'a reflection of the extraordinary progress in AD care that is ongoing and is indeed revolutionizing care.' Having 'two new nonsteroidal topical therapies is quite significant,' he added in an interview with Medscape Dermatology . 'Patients have long been dissatisfied with topical options, which have been shackled by safety concerns, some real, some not, and intolerance, such as application site stinging.' The update comes just over a year after the release of AAD's 2023-2024 adult AD guidelines on treatment with topical and systemic therapies, underscoring the rapid pace of therapeutic development for AD. The update was initiated following the FDA approval of multiple new therapies and newly published high-certainty evidence supporting their use, prompting the AAD to incorporate this data into its existing guidance, according to the authors. Strong Recommendations for Four New Agents The guideline workgroup applied the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework to assess new data and formulate treatment recommendations. According to the authors, all four therapies received 'strong' recommendations based on high-certainty evidence: Tapinarof cream 1% : A nonsteroidal aryl hydrocarbon receptor agonist approved in 2024 for moderate to severe AD. In four trials (n = 1169), once-daily use over 8-12 weeks resulted in statistically and clinically significant improvements in investigator's global assessment (IGA), eczema area and severity index (EASI)-75, and itch scores. : A nonsteroidal aryl hydrocarbon receptor agonist approved in 2024 for moderate to severe AD. In four trials (n = 1169), once-daily use over 8-12 weeks resulted in statistically and clinically significant improvements in investigator's global assessment (IGA), eczema area and severity index (EASI)-75, and itch scores. Roflumilast cream 0.15% : A phosphodiesterase-4 inhibitor approved in 2024 for mild to moderate AD. Clinical trials (n = 1427) demonstrated significant improvements in IGA and EASI-75 after 4 weeks. : A phosphodiesterase-4 inhibitor approved in 2024 for mild to moderate AD. Clinical trials (n = 1427) demonstrated significant improvements in IGA and EASI-75 after 4 weeks. Lebrikizumab : An interleukin (IL)-13-targeting monoclonal antibody approved in 2024 for moderate to severe AD. In over 1700 patients, treatment with or without topical corticosteroids led to marked improvements in clinical and patient-reported outcomes. : An interleukin (IL)-13-targeting monoclonal antibody approved in 2024 for moderate to severe AD. In over 1700 patients, treatment with or without topical corticosteroids led to marked improvements in clinical and patient-reported outcomes. Nemolizumab (with topical therapy): An IL-31 receptor inhibitor approved in 2024 for patients aged 12 years or older inadequately controlled with topical therapies. In three trials (n = 1256), nemolizumab plus topical corticosteroids (with or without topical calcineurin inhibitor) led to significant reductions in itch and improvements in EASI-75 and Dermatology Life Quality Index. Updated Treatment Algorithm The guideline includes an updated treatment algorithm to help clinicians integrate these agents into clinical practice. It emphasizes: All four newly recommended therapies are indicated with strong recommendation symbols in the updated algorithm figure. Real-World Considerations Sidbury emphasized that having multiple high-certainty options creates new opportunities but also new challenges in decision-making. 'Such choice is a lovely problem to have,' he said, but he urged clinicians to look beyond efficacy. For example, 'a patient with baseline ocular difficulties would want to be aware that IL-4/13 or IL-13 biologics can cause or exacerbate conjunctivitis,' he explained. 'Nemolizumab or a JAK inhibitor, neither of which carries ocular risk, might be a good choice. Similarly, patients with cardiovascular risk may want to avoid JAK inhibitors due to their boxed warning.' Treatment selection, he said, should be rooted in shared decision-making: 'It's important to weigh evidence alongside a patient's comorbidities, preferences, and tolerability history.' Remaining Gaps and Considerations Despite the promising data, the authors acknowledged important limitations. Most trials were short-term (≤ 24 weeks), and the long-term safety, durability of response, and comparative effectiveness of these agents remain unknown. Cost is another factor. The authors noted, 'costs for the considered therapies may be prohibitive without adequate insurance coverage.' As such, they stressed the importance of a shared decision-making process that weighs efficacy, safety, and affordability. Clinical Impact and Future Directions The update is expected to have an immediate impact in clinical settings. 'Atopic dermatitis care has long been an 'off-label' affair,' Sidbury said. 'Prior to 2017, the only FDA-approved systemic therapy for AD was systemic steroids. Since then, we've seen numerous novel topical and systemic therapies approved with many more on the way. Better evidence plus more choices equals improved outcomes.' Still, more research is needed. Sidbury pointed to the importance of identifying which therapies may work best for specific patient subtypes — by age, race, gender, or AD phenotype. 'We don't know yet, but the answer is likely yes. This gets at personalized medicine — and that's where we're headed,' he said, noting that future treatment may be guided by inflammatory signatures or genotyping. While this focused update offers valuable clarity on incorporating new treatment options for adult AD, further research is needed, according to the authors. The workgroup called for real-world data, head-to-head trials, and longer-term outcome studies. The authors also noted pediatric guideline updates are expected in a future publication. This study was funded in total by internal funds from the American Academy of Dermatology. Sidbury disclosed he serves as an advisory board member for Pfizer, receiving honoraria; as a principal investigator for Regeneron, receiving grants and research funding; as an investigator for Brickell Biotech, and Galderma USA, receiving grants and research funding; and as a consultant for Galderma Global and Microes, receiving fees or no compensation. Other authors reported having financial disclosures with many pharmaceutical companies. : Biologics, JAK inhibitors, and immunosuppressants remain key choices for refractory disease.
